CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-23). The draft was written by AI, the existence of all 2 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 1568 · Search date 2026-07-23 · Methodology v0.6

Hearing-aid intervention,
does it really help with Prevention of cognitive decline and dementia in older adults with hearing loss?

30-Second Summary
D
Evidence Grade D · 34 · Safety unknown
Three-year cognitive decline was not reduced in the overall randomized cohort
What the
research shows
Hearing-aid-based intervention is graded D for preventing cognitive decline or dementia in older adults with hearing loss. In all 977 ACHIEVE participants, the between-group difference in three-year global cognitive change was 0.002 SD (95% CI -0.077 to 0.081), p=0.96, a null primary endpoint. The result in the higher-risk ARIC population was a prespecified sensitivity and subgroup finding, not a replacement for the null overall primary analysis, and incident dementia prevention was not established.
What the
ads claim
Better hearing and communication, or observational associations, may be expanded into proven causal prevention of dementia.
*

Useful facts when choosing a product

  • The ACHIEVE hearing intervention included hearing aids, fitting adjustments, and audiological rehabilitation counseling.
  • The total cohort's three-year global cognition primary endpoint did not differ from health education.
  • Hearing aids can cause ear irritation, pressure, feedback, discomfort, and adaptation burden, although no significant intervention-attributed adverse events were reported in ACHIEVE.
Gap Measurement · Verdict 1568 · D 34
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

The ACHIEVE intervention combined hearing aids, fitting, and audiological rehabilitation counseling and compared it with health education. The overall primary analysis was null; the positive signal depended on differing effects by recruitment source. A systematic review by Sanders and colleagues found 17 studies, 3,526 participants, and 50 different cognitive tests and called the cognitive effect controversial. Associations from observational studies were not treated as randomized causal effects.

02

Why this is classified as D (34)

The ACHIEVE total-cohort primary endpoint was null, with a difference of 0.002 SD and p=0.96, incident dementia prevention was not established, and earlier evidence was inconsistent, yielding D with 34 points.

Counterpoint. Improved hearing, communication, and quality of life are separate outcomes from prevention of cognitive decline or dementia.

Rejudgment record. New verdict — Applied rule ② because the ACHIEVE total-cohort three-year global cognition primary endpoint was null, did not substitute the recruitment-source subgroup signal for the overall result, and incorporated absent direct incident-dementia evidence and prior inconsistency

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
Prevention of cognitive decline in the overall older population with hearing lossDThe ACHIEVE total-cohort primary endpoint was null with p=0.96.
Prevention of incident dementiaDNo completed randomized evidence designed and powered to establish fewer incident dementia cases was found.
Improvement in hearing and communicationCDirect auditory benefit is a separate outcome and does not raise the cognition or dementia-prevention grade.

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Lin FR et al. 2023Multicenter randomized active-controlled trial487United States NIH public funding; some donated devices and disclosed author interestsThree-year change in a standardized global cognition scoreOverall difference 0.002 SD (95% CI -0.077 to 0.081), p=0.96; null primary endpoint.Key large randomized trial
Sanders ME, Kant E, Smit AL, Stegeman I. 2021Systematic review50Academic researchMultiple cognitive domains and global cognitionResults were heterogeneous and controversial, precluding meta-analysis.Pre-ACHIEVE inconsistency assessment
§

Receipt — 2 References

All 2 cited sources were verified for existence at the original page (as of 2026-07-23).

Lin FR, Pike JR, Albert MS, et al. Hearing intervention versus health education control to reduce cognitive decline in older adults with hearing loss in the USA (ACHIEVE): a multicentre, randomised controlled trial. Lancet. 2023;402(10404):786-797. PMID: 37478886. DOI: 10.1016/S0140-6736(23)01406-X.
checked
Sanders ME, Kant E, Smit AL, Stegeman I. The effect of hearing aids on cognitive function: A systematic review. PLoS One. 2021;16(12):e0261207. PMID: 34972121. DOI: 10.1371/journal.pone.0261207.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-23 · Corrections: none

Cite this verdict

Hearing-aid intervention x prevention of cognitive decline and dementia Evidence Grade D card
[Chamgap] Hearing-aid intervention x prevention of cognitive decline and dementia — Evidence Grade D·34. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/cognition/hearing-aid-intervention-cognitive-decline-dementia-prevention/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.